Skip to content

Study · Systematic review · 2021

2 results

Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: A meta-analysis of randomized controlled trials.

Simental-Mendía LE, Sánchez-García A, Linden-Torres E, Simental-Mendía M

British journal of clinical pharmacology29 Apr 2021Cited by 53 (Europe PMC)

PMID33835520 (opens in a new tab)DOI10.1111/bcp.14855 (opens in a new tab)PepBankPUB-33835520
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In the pooled randomized trials, liraglutide significantly increased circulating adiponectin concentrations.

    In plain wordsIn people in the pooled trials, liraglutide raised blood adiponectin levels.

    Peptide
    Liraglutide
    Outcome
    IncreaseCirculating adiponectin, liraglutide subgroup
    Study

    n: not reported in source

    Outcome group
    Adipokines · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    WMD
    0.55 μg/mL
    liraglutide

    Source sentences

    Summary
    liraglutide had a significant effect on adiponectin (WMD: 0.55 μg/mL, 95% CI: 0.04, 1.06, P = .04)
    1 context sentence
    Summary · context
    This systematic review and meta-analysis included randomized controlled trials investigating the effect of GLP-1 RA on circulating adiponectin concentrations.

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In 20 randomized trials, GLP-1 receptor agonist treatment, including liraglutide, significantly increased circulating adiponectin concentrations.

    In plain wordsIn people in 20 pooled trials, GLP-1 drugs including liraglutide raised blood adiponectin levels.

    Peptide
    Liraglutide
    Outcome
    IncreaseCirculating adiponectin, all GLP-1 receptor agonists
    Study

    n = 1,497

    Outcome group
    Adipokines · Metabolic and weight

    Measurements

    WMD
    0.59 μg/mL
    all GLP-1 RAs

    Source sentences

    Summary
    A meta-analysis of 20 randomized controlled trials involving 1497 individuals demonstrated a significant increase in adiponectin levels after GLP-1 RA administration (weighted mean difference [WMD]: 0.59 μg/mL, 95% confidence interval [CI]: 0.10, 1.08, P = .02).
    1 context sentence
    Summary · context
    This systematic review and meta-analysis included randomized controlled trials investigating the effect of GLP-1 RA on circulating adiponectin concentrations.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.